Dravet syndrome (DS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Indication name: Dravet syndrome (DS)

Dravet syndrome (DS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Dravet syndrome (DS) is a genetic epilepsy of childhood characterized by a variety of drug-resistant seizures often induced by fever, presenting in previously healthy children, and which frequently leads to cognitive and motor impairment. Around 85% of DS cases are due to a mutation or deletion in the SCN1A gene, encoding a voltage-gated sodium channel essential for the excitability of neurons. Most mutations are de novo but in 5-10% they are familial and often part of the generalized epilepsy with febrile seizures-plus spectrum.

Dravet Syndrome is classified as a genetic epilepsy syndrome and an epileptic encephalopathy, defined as an epilepsy syndrome associated with encephalopathic features that present or worsen after the onset of epilepsy.

According to Thelansis estimates, Dravet syndrome affects 1:15,700 individuals in the U.S., or 0.0064% of the population . Approximately 80-90% of those, or 1:20,900 individuals, have both an SCN1A mutation and a clinical diagnosis of DS. This represents an estimated 0.17% of all epilepsies.

Competitive landscape of Dravet syndrome (DS) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Dravet syndrome (DS) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Dravet syndrome (DS) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Dravet syndrome (DS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

S. No        Asset        Company           Partner          Phase

1        Diacomit        Laboratoires Biocodex        Meiji Seika Pharma        Approved

2        Epidiolex        GW Pharmaceuticals plc        N/A        Approved

3        Fintepla        Zogenix, Inc.        Nippon Shinyaku        NDA

4        Onfi        H. Lundbeck A/S        Daiichi Sankyo; Alfresa Pharma        III

5        EPX-200        Epygenix Therapeutics, Inc.        N/A        II

6        OV935        Ovid Therapeutics, Inc.        Takeda        II

7        Translarna        PTC Therapeutics, Inc.        UPenn        II

8        Zygel        Zynerba Pharmaceuticals, Inc.        N/A        II

9        DiazePen        Xeris Pharmaceuticals, Inc.        N/A        I

10        EPX-100        Epygenix Therapeutics, Inc.        N/A        I

11        EPX-300        Epygenix Therapeutics, Inc.        N/A        I

12        XEN901        Xenon Pharmaceuticals, Inc.        N/A        I

13        Dravet Syndrome Program (NeuCyte/Trillium)        NeuCyte, Inc.        Trillium Therapeutics        Preclinical

14        OPK-88001        Opko Health        N/A        Preclinical

15        SPN-817        Supernus Pharmaceuticals, Inc.        Global Drug Development Centre        Preclinical

16        STK-001        Stoke Therapeutics, Inc.        N/A        Preclinical